EUCAAD

European Consortium for Anticancer Antibody Development

 Coordinatore KAROLINSKA INSTITUTET 

 Organization address address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177

contact info
Titolo: Ms.
Nome: Maria
Cognome: Von Witting
Email: send email
Telefono: +46 8 517 758 78
Fax: +46 8 517 706 90

 Nazionalità Coordinatore Sweden [SE]
 Totale costo 7˙862˙359 €
 EC contributo 5˙989˙862 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2007-A
 Funding Scheme CP-FP
 Anno di inizio 2008
 Periodo (anno-mese-giorno) 2008-05-01   -   2012-04-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET

 Organization address address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177

contact info
Titolo: Ms.
Nome: Maria
Cognome: Von Witting
Email: send email
Telefono: +46 8 517 758 78
Fax: +46 8 517 706 90

SE (STOCKHOLM) coordinator 0.00
2    BIOINVENT INTERNATIONAL AB

 Organization address address: Soelvegatan 41
city: LUND
postcode: 22370

contact info
Titolo: Mr.
Nome: Stefan
Cognome: Ericsson
Email: send email
Telefono: +46 46 286 8550
Fax: +46 46 211 0806

SE (LUND) participant 0.00
3    MARTIN-LUTHER-UNIVERSITAET HALLE-WITTENBERG

 Organization address address: UNIVERSITAETSPLATZ 10
city: HALLE (Saale)
postcode: 6099

contact info
Titolo: Dr.
Nome: Peter
Cognome: Waehner
Email: send email
Telefono: +49 0 345 552 1452
Fax: +49 0 345 552 7396

DE (HALLE (Saale)) participant 0.00
4    PHILOCHEM AG

 Organization address address: WOLFGANG PAULI STRASSE 10
city: ZURICH
postcode: 8093

contact info
Titolo: Dr.
Nome: Eveline
Cognome: Trachsel
Email: send email
Telefono: +44 633 78 64
Fax: +44 633 14 81

CH (ZURICH) participant 0.00
5    PROTAGEN AG

 Organization address address: Otto-Hahn-Strasse 15
city: DORTMUND
postcode: 44227

contact info
Titolo: Mr.
Nome: Sven
Cognome: Rüger
Email: send email
Telefono: +49 231 9742 6300
Fax: +49 231 9742 6301

DE (DORTMUND) participant 0.00
6    THROMBOGENICS NV

 Organization address address: Herestraat
city: LEUVEN
postcode: 3000

contact info
Titolo: Dr.
Nome: Jean Marie
Cognome: Stassen
Email: send email
Telefono: +32 16 34 61 94
Fax: +32 16 34 61 34

BE (LEUVEN) participant 0.00
7    UNIVERSITA DEGLI STUDI DI TORINO

 Organization address address: Via Giuseppe Verdi 8
city: TORINO
postcode: 10124

contact info
Titolo: Dr.
Nome: Eugenio
Cognome: Rinaldi
Email: send email
Telefono: +39 011 670 5441
Fax: +39 011 670 5413

IT (TORINO) participant 0.00
8    UNIVERSITA DEGLI STUDI GABRIELE D'ANNUNZIO DI CHIETI-PESCARA

 Organization address address: Via dei Vestini 31
city: CHIETI
postcode: 66013

contact info
Titolo: Dr.
Nome: Luciana
Cognome: Gallo
Email: send email
Telefono: 390872000000
Fax: 390872000000

IT (CHIETI) participant 0.00
9    UNIVERSITE D'AIX MARSEILLE

 Organization address address: Boulevard Charles Livon 58
city: Marseille
postcode: 13284

contact info
Titolo: Ms.
Nome: Celine
Cognome: Damon
Email: send email
Telefono: +33 4 91 99 85 95

FR (Marseille) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

cancer    cell    anti    ror    scientific    specifically    angiogenesis    immune    tumours    therapeutic    induce    therapy    amot    basic    amotl    smes    discovery    antibodies    clinical    cells    antibody    cll    evaluation    tumor    therapies    antigens    eucaad    tumour    treatment    angiogenic    worked    urgently    consists   

 Obiettivo del progetto (Objective)

'Cancer is the second leading cause of death in European countries, and one of the most imminent health problems in the developed world. Innovative, so-called targeted therapies are urgently needed that aim specifically at cancer cells or to cells of the stroma that support tumor growth. The ultimate goal of a targeted therapy is to increase anti-tumor efficacy with lowest possible side effects. Rapid and efficient translation of basic scientific advances into reagents, and targeted molecular leads for preclinical and clinical research and development based on scientific rationales and state-of-the-art technologies, optimally requires an interdisciplinary, collaborative, team-oriented approach. EUCAAD represents a virtual research institute in Europe and consists of 9 research participants including 4 SMEs devoted to the discovery and evaluation of new antibodies for therapy of human cancers. The consortium consists of researchers from SMEs and scientific and clinical centres that have gained international acclaim in this area of research, many of who have worked together in previous EU funded applications e.g. ANGIOSTOP, EUCAPS, ESTDAB and ENACT. Within the consortium there is unique expertise regarding target discovery, target validation, antibody production and initiation of clinical trials. As part of its efforts to translate laboratory research into viable cancer therapies the individual partners has accumulated an extensive portfolio of intellectual property providing a competitive edge to this application. The focus of the grant is the development and evaluation of antibodies against new target structures on tumour cells and blood vessels supplying tumours which are responsible for tumour angiogenesis, progression and metastasis. Collectively, the activities of this consortium can improve the cancer treatment standards in Europe and provide economic benefit to European biotechnology and pharmaceutical research by providing novel immunopharmaceuticals.'

Introduzione (Teaser)

European researchers have developed immunotherapeuticals that raise specific adaptive immune responses against cancer. Using our body's immune system to fight cancer is emerging as a potential treatment regimen.

Descrizione progetto (Article)

Cancer therapy remains a clinical challenge since generalised treatments such as radiotherapy and chemotherapy pose serious complications for normal organs. As a result, effective regimens are urgently required that specifically target cancer cells, thereby minimising undesirable side-effects.

The scientific objective of the EU-funded 'European consortium for anticancer antibody development' (EUCAAD) project was to identify novel cancer-related targets for raising therapeutic antibodies. The main focus was on tumour- and angiogenesis-associated antigens.

Targeting the vessel compartment of growing tumours has been recognised as a potential approach for inhibiting cancer. At the same time, the specificity of antibodies could be exploited to target antigens present on the surface of cancer cells or to bind and deplete growth factors required for tumour maintenance and growth.

EUCAAD partners combined these two approaches to generate a vaccine against the angiomotin (AMOT) protein, which is selectively expressed on endothelial cells of angiogenic tissues. When used in a pre-clinical mouse model, inhibition of neovascularisation and tumour growth was observed and attributed to natural killer cell-mediated cell cytotoxicity. Antibodies against other AMOT partners such as AMOTL1 and AMOTL2 were also proposed as potential avenues for therapeutic exploitation.

The consortium also worked on the development of various antibodies to induce chronic lymphocytic leukemia (CLL) based on a molecule called ROR1. Targeting of ROR1, which is implicated in Wnt signalling, was shown to induce apoptosis of CLL cells.

Overall, the EUCAAD project successfully integrated basic science with translational research to identify angiogenic- and cancer-associated targets. The project deliverables have the potential to lead to the development of novel anti-cancer drugs and vaccines, hopefully with promising therapeutic outcomes.

Altri progetti dello stesso programma (FP7-HEALTH)

SENATOR (2012)

Development and clinical trials of a new Software ENgine for the Assessment & Optimization of drug and non-drug Therapy in Older peRsons

Read More  

ACUSEP (2010)

Integrated whole blood acoustophoresis and homogeneous nucleic acid detection cartridge for rapid sepsis diagnostics

Read More  

SUPERSIST (2013)

Towards clinical translation of new gene targeting technologies for correcting inherited mutations and empowering adoptive immunotherapy of cancer

Read More